All In Biotech

Guides

Free drug databases: the main ones and what each is for

A guide to the main free drug databases from FDA, NLM and CMS: what Drugs@FDA, DailyMed, the Orange Book, FAERS and others hold, and which to use when.

By the All In Biotech editorial team · Published November 18, 2026 · 6 min read

The main free drug databases are run by the US government: Drugs@FDA for approval history, DailyMed for current labels, the Orange Book and Purple Book for patents, exclusivity and equivalence, FAERS for adverse event reports, ClinicalTrials.gov for studies, and CMS datasets for Medicare spending. Each answers a different question, and most confusion comes from looking in the wrong one.

This guide explains what each database holds, what it leaves out, and where this site's free tools combine them.

The short list

DatabaseRun byUse it for
Drugs@FDAFDA (CDER)Approval dates, application numbers, approval letters, reviews, label history
DailyMedNational Library of MedicineThe current label (prescribing information) for a marketed product
Orange BookFDAPatents, exclusivity and therapeutic equivalence codes for small-molecule drugs
Purple BookFDALicensed biologics, biosimilars, interchangeability and reference product exclusivity
FAERSFDAAdverse event reports submitted after approval
openFDAFDAMachine-readable access to labels, adverse events, recalls and Drugs@FDA data
ClinicalTrials.govNational Library of MedicineRegistered clinical studies, their design, status and posted results
NDC DirectoryFDANational Drug Codes, packagers and package sizes
RxNormNational Library of MedicineStandard names and codes that link drug vocabularies
CMS dataCenters for Medicare and Medicaid ServicesMedicare Part D and Part B spending by drug

Approval history: Drugs@FDA

Drugs@FDA is the starting point for the question "when was this drug approved, and for what?" It covers most drug products approved since 1939, and for products approved from 1998 onward it usually links the approval letters, FDA's reviews and each version of the label.

The database is organized by application number. A brand-name drug has a New Drug Application (NDA) or a Biologics License Application (BLA); a generic has an Abbreviated New Drug Application (ANDA). Different strengths or dosage forms can sit under different applications, so one drug name can return several results.

Two limits matter. Drugs@FDA covers drugs regulated by FDA's Center for Drug Evaluation and Research (CDER), so most vaccines, blood products and cell and gene therapies, which are approved by the Center for Biologics Evaluation and Research, are not in it. And it records what was approved, not what was rejected: FDA only began publishing complete response letters in a central openFDA collection in 2025.

For a step-by-step walk-through, see how to search Drugs@FDA.

Current labels: DailyMed

When you need the label as it stands today, use DailyMed. Companies submit labels to FDA in a structured format, and the National Library of Medicine publishes them on DailyMed. It includes prescription and over-the-counter drugs, and many products that Drugs@FDA does not list in detail, such as repackaged products.

DailyMed shows one label per product listing, so a single drug can have dozens of entries from different packagers. Check the labeler name and the "Revised" date. If you want to understand what each label section means, see how to read an FDA drug label.

Patents, exclusivity and generics: the Orange Book and Purple Book

The Orange Book lists small-molecule drugs approved under the Federal Food, Drug, and Cosmetic Act, along with the patents the brand company has listed, the exclusivity periods FDA has granted, and therapeutic equivalence codes that tell pharmacists which generics can substitute for the brand.

The Purple Book does a similar job for biologics licensed under the Public Health Service Act. It shows which products are biosimilar to or interchangeable with a reference product and the dates of reference product exclusivity.

This site does not hold Orange Book or Purple Book data, so go to FDA for both. The differences between the two are covered in Orange Book vs Purple Book.

Safety: FAERS and MedWatch

The FDA Adverse Event Reporting System holds reports of suspected side effects, medication errors and product problems sent in by manufacturers, health professionals and patients. FDA's pages now describe it under the FDA Adverse Event Monitoring System (AEMS), and the reports can be searched through the FAERS Public Dashboard or the openFDA drug adverse event API.

FAERS holds about 21 million reports. They are useful for spotting patterns, but a report does not show the drug caused the event, and counts are not rates. Vaccine reports go to a separate system, VAERS.

This site's FAERS Monitor shows the most reported reactions, seriousness and a disproportionality screen for any drug. The guide to searching FAERS explains what the numbers can and cannot support.

Clinical trials: ClinicalTrials.gov

ClinicalTrials.gov is the federal registry of clinical studies. Under section 801 of the FDA Amendments Act of 2007, most controlled trials of FDA-regulated drugs beyond phase 1 must be registered, and many must post results. Each record shows the sponsor, phase, design, enrollment, primary outcomes, locations and status.

Search by the active ingredient as well as the brand name, since early-phase trials often use a code name. This site's trial search filters ClinicalTrials.gov records by therapeutic area, phase and ingredient.

Codes and names: the NDC Directory and RxNorm

The NDC Directory lists the National Drug Code for each marketed package, the labeler and the package size. It is the database to use when you have a code from a pharmacy claim or a package and need to know what it is.

RxNorm, from the National Library of Medicine, gives each clinical drug a standard name and identifier and maps between the vocabularies that pharmacy and hospital systems use. It matters most if you are working with data from several sources.

Spending: CMS Medicare datasets

CMS publishes Medicare Part D and Part B spending by drug each year. The figures are gross spending before manufacturer rebates, along with beneficiary counts and, for Part B, the average sales price payment limit.

As of November 2026 the latest year is 2024. In this site's copy of the data, total gross Part D drug spending was $288.7 billion in 2024 and Part B drug spending was $60.8 billion. Eliquis had the highest Part D spending, at $20.77 billion.

The Medicare drug spending tool on this site lets you sort the Part D and Part B tables by total spend, growth, spend per beneficiary or number of beneficiaries.

Consumer information: MedlinePlus

For plain-language drug information written for patients, the National Library of Medicine's MedlinePlus drug pages explain what a drug is used for, how to take it and common side effects. It is a reference, not a substitute for the label or for a clinician.

Combining the sources

Most real questions need more than one database. A few common examples:

  1. "What is approved for this condition?" Labels list indications in free text, so there is no single FDA field to search. This site's conditions pages group approved drugs by indication.
  2. "Is a generic available?" Check the Orange Book for therapeutic equivalence codes, then DailyMed or the NDC Directory for marketed products.
  3. "What is known about a new drug's safety?" Start with the label's warnings, then FAERS for postmarketing reports, then ClinicalTrials.gov for ongoing studies.
  4. "How much does Medicare spend on it?" Use the CMS datasets, keeping in mind that the figures are before rebates.

What free databases cannot tell you

Public databases record regulatory facts: what FDA approved, what the label says, what was reported. They do not tell you whether a drug is right for a person, what a patient will pay at the pharmacy, or what net price an insurer pays after rebates. Unapproved applications and the contents of pending reviews are mostly confidential.

Data also lags. Drugs@FDA and openFDA are updated on regular schedules, CMS spending data arrives more than a year after the period it covers, and FAERS is released quarterly. Check the date on any figure before you rely on it. This site's methods page lists the source and refresh schedule for each tool.

Frequently asked questions

What is the official FDA drug database?
Drugs@FDA is FDA's database of approved brand-name and generic drugs, with approval histories, letters, reviews and labels for most products approved since 1998.
Is there a free database of drug labels?
DailyMed, run by the National Library of Medicine, holds the current labels that companies submit to FDA, and it is free to search and download.
Where can I find drug side effect reports?
FDA publishes adverse event reports through the FAERS Public Dashboard and openFDA, and this site's FAERS Monitor summarizes them for any drug.
Do I need an account to use these databases?
No. The FDA, NLM and CMS databases described here are free and open without registration.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading